Sage Journals: Discover world-class research

Abstract

Background:

Prognosis of patients with metastatic melanoma has improved due to the advent of antibodies targeting the programmed cell death protein-1 (PD-1). However, therapeutic outcomes from anti-PD-1 therapy widely differ among patients. Biomarkers for outcome are needed as these may influence patient selection and treatment decision.

Methods:

Data of patients with metastatic melanoma treated with anti-PD-1 were retrospectively reviewed. Baseline biochemical (serum lactate dehydrogenase [LDH] levels, complete blood count) and clinical characteristics were evaluated to identify predictors of progression-free survival (PFS) and overall survival (OS). PFS and OS were assessed using Kaplan-Meier and Cox models. The comparison of predictive power of independent predictors for response to anti-PD-1 was evaluated by receiver operating characteristic (ROC) curves.

Results:

Overall, 173 patients were included. Low metastases burden, normal baseline LDH levels, and high relative lymphocyte count (RLC) were associated with favorable outcomes (p < 0.01). According to ROC curves, RLC >17.5% improved survival outcomes. PFS was 3.7 and 15.8 months for patients with RLC <17.5% and >17.5%, respectively (p = 0.004); OS was 5.0 and 33.6 months for patients with RLC <17.5% and >17.5%, respectively (p < 0.001). Stratification of patients according to these variables showed that survival outcomes strongly differ in patients with 3 of 3 compared to those with 2, 1, and none of these 3 factors present (p < 0.001).

Conclusions:

Metastases burden, LDH levels, and RLC are independent baseline characteristics associated with outcome in patients with melanoma receiving anti-PD-1. Further investigations are needed to clarify if evaluation of these parameters can translate into clinical strategy and apply to patient selection.

Keywords

Melanoma immunotherapy anti-PD-1 leukocytes LDH prognosis

Get full access to this article

View all access options for this article.

References

American Cancer Society. Cancer Facts and Figures 2018. Atlanta: American Cancer Society; 2018.

Leiter

Eigentler

Garbe

Epidemiology of skin cancer. Adv Exp Med Biol 2014; 810: 120–140.

Gershenwald

Scolyer

Hess

et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472–492.

Hodi

O’Day

McDermott

et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.

Weber

D’Angelo

Minor

et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375–384.

Ribas

Puzanov

Dummer

et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908–918.

Robert

Long

Brady

et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320–330.

Robert

Schachter

Long

et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521–2532.

Robert

Ribas

Hamid

et al. Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. J Clin Oncol 2016; 34 (15 suppl): 9503–9503.

10.

Weber

Hodi

Wolchok

et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017; 35: 785–792.

11.

Freeman-Keller

Kim

Cronin

Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016; 22: 886–894.

12.

Roszyk

HAydu

Hess

et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 2016; 14: 168.

13.

Hugo

Zaretsky

Sun

Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016; 165: 35–44.

14.

Taube

Klein

Brahmer

et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20: 5064–5074.

15.

Sacdalan

Lucero

Sacdalan

DL.

Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther 2018; 11: 955–965.

16.

Garnier

Zaragoza

Bénéton

et al. High neutrophil-to-lymphocyte ratio before starting anti-PD1 immunotherapy predicts poor outcome in patients with metastatic melanoma. J Am Acad Dermatol. Epub ahead of print 12 Mar 2018.

17.

Chasseuil

Saint-Jean

Chasseuil

et al. Blood predictive biomarkers for nivolumab in advanced melanoma. Acta Derm Venereol 2018; 98: 406–410.

18.

Failing

Yan

Porrata

et al Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients. Melanoma Res 2017; 27: 596–600.

19.

Weide

Martens

Hassel

et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 2016; 22: 5487–5496.

20.

Hopkins

Rowland

Kichenadasse

et al. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer 2017; 117: 913–920.

21.

Heidelberger

Goldwasser

Kramkimel

et al. Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. Invest New Drugs 2017; 35: 842–847.

22.

Nosrati

Tsai

Goldinger

et al. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer 2017; 116: 1141–1147.

23.

Nakamura

Kitano

Takahashi

et al. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget 2016; 7: 77404–77415.

24.

Larkin

Lao

Urba

et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 2015; 1: 433–440.

25.

Perier-Muzet

Gatt

Péron

et al. Association of immunotherapy with overall survival in elderly patients with melanoma. JAMA Dermatol 2018; 154: 82–87.

26.

Indini

DI Guardo

Cimminiello

et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. Cancer Res Clin Oncol 2019; 145: 511–521.

27.

Gandini

Ferrucci

Botteri

et al. Prognostic significance of hematological profiles in melanoma patients. Int J Cancer 2016; 139: 1618–1625.

28.

Zaragoza

Caille

Beneton

et al. Neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol 2016; 174: 146–151.

29.

Ferrucci

Ascierto

Pigozzo

et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 2016; 27: 732–738.

30.

Martens

Wistuba-Hamprecht

Geukes Foppen

et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 2016; 22: 2908–2918.

Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma

Abstract

Background:

Methods:

Results:

Conclusions:

Keywords

Get full access to this article

References